Medical Devices

A new partnership aims to put advanced digital tools in more dentists' hands, tackling key adoption barriers with enhanced local support and integrated workflows.

A new study confirms Theranica's migraine wearable won't disrupt glucose monitors, a major breakthrough for 4.5 million Americans with both conditions.

Despite missing its primary goal, Cadrenal Therapeutics' drug CAD-1005 drastically cut deadly blood clots, setting up a crucial FDA meeting for a new path forward.

Medtronic's diabetes arm hits the road for its IPO, seeking to raise up to $784M in a major test of investor appetite for specialized medtech firms.

A new report on 1,800+ patients reveals a model for obesity care that preserves muscle, sustains weight loss, and may solve the GLP-1 cost crisis.

Fresh off strong 2025 earnings, AtriCure will detail its growth strategy and innovative cardiac portfolio at a major life sciences conference.

After a pivotal trial failure, Alector will present its new strategy at a key health conference, focusing on its innovative brain-delivery platform.

NorthX Biologics and Demeetra have partnered to offer a streamlined, royalty-free path from gene to GMP, tackling key bottlenecks for biotech startups.

Fort Worth Plastic Surgery's new partnership with a PE-backed group highlights a major industry shift, raising questions about growth, autonomy, and patient care.

The maker of Wegovy and Ozempic announces a massive price cut. We explore what this means for patients, competitors, and the future of drug pricing.

New data on MCO-010 gene therapy identifies ideal patients for Retinitis Pigmentosa, a key step as the one-time injection advances toward FDA approval.

With pivotal data imminent for its blockbuster hopeful AXPAXLI, Ocular Therapeutix faces a critical month of investor meetings amid commercial headwinds.

A pivotal trial for a rare muscle disease failed its main goal, but promising data in a specific patient group offers a new, complex path forward.

With no approved therapies for Hepatitis E, Atea Pharmaceuticals' new drug shows potent preclinical results, offering a potential lifeline for vulnerable patients.

With its Moda-flx system cleared by the FDA, Diality hires M&A expert Peter Donato to navigate the path to commercialization in the $92B dialysis market.

As Autolus heads to key investor conferences, its strong AUCATZYL® sales and deep pipeline face scrutiny against mounting losses and a curious PR misstep.

A new report shows patients are rejecting 'overdone' looks for subtle, strategic care, driven by Ozempic, menopause, and a desire for authenticity.

The Emerging Growth Conference showcases tomorrow's innovators. But with paid presentations, investors must look past the hype to find true value.

A new partnership brings an FDA-designated breakthrough device to more patients, fueled by a key Medicare payment that could reshape the trauma market.

Beam Therapeutics is set to announce its 2025 financial results and a new liver-targeted therapy, a key moment for its base editing platform and investors.